FY2026 EPS Estimates for Nanobiotix Decreased by Analyst

Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) – Research analysts at Leerink Partnrs lowered their FY2026 earnings estimates for Nanobiotix in a report released on Monday, November 24th. Leerink Partnrs analyst J. Chang now forecasts that the company will earn $2.32 per share for the year, down from their prior estimate of $2.36. The consensus estimate for Nanobiotix’s current full-year earnings is ($1.18) per share.

NBTX has been the topic of several other reports. HC Wainwright reissued a “buy” rating on shares of Nanobiotix in a report on Tuesday, November 4th. Weiss Ratings reissued a “sell (d-)” rating on shares of Nanobiotix in a research note on Wednesday, October 8th. Leerink Partners reissued an “outperform” rating on shares of Nanobiotix in a report on Tuesday. Finally, Wall Street Zen raised shares of Nanobiotix to a “hold” rating in a report on Saturday, October 25th. Three equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Nanobiotix currently has a consensus rating of “Hold” and a consensus target price of $11.00.

Nanobiotix Trading Down 3.5%

Shares of Nanobiotix stock opened at $21.23 on Wednesday. Nanobiotix has a fifty-two week low of $2.76 and a fifty-two week high of $30.35. The firm has a 50-day simple moving average of $20.35 and a two-hundred day simple moving average of $11.15.

Institutional Investors Weigh In On Nanobiotix

An institutional investor recently bought a new position in Nanobiotix stock. Optiver Holding B.V. purchased a new position in Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 5,356 shares of the company’s stock, valued at approximately $101,000. 38.81% of the stock is currently owned by institutional investors and hedge funds.

Nanobiotix Company Profile

Nanobiotix SA, a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer.